UniProt Q15788
Nuclear receptor coactivator 1 (Q15788)
Nuclear receptor coactivator 1 (UniProt Q15788), EC 2.3.1.48: 276 experimental structures on GenesisL1, 17 ligands bound, 17 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q15788
- Protein
- Nuclear receptor coactivator 1
- EC
- 2.3.1.48
- Experimental structures
- 276
- Predicted models
- 0
- Ligands
- 17
- Pockets
- 17 · 3 records with a druggable one
Structures
276 records of Q15788 in the MolNFT archive: 276 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1TFC | Crystal structure of the ligand-binding domain of the estrogen-related receptor gamma in complex… | x-ray diffraction | C, D | — | — |
| 1TFC | Crystal structure of the ligand-binding domain of the estrogen-related receptor gamma in complex… | x-ray diffraction | C, D | — | — |
| 1XIU | Crystal structure of the agonist-bound ligand-binding domain of Biomphalaria glabrata RXR | x-ray diffraction | E, F | — | — |
| 1XIU | Crystal structure of the agonist-bound ligand-binding domain of biomphalaria glabrata rxr | x-ray diffraction | E, F | — | — |
| 1ZAF | Crystal structure of estrogen receptor beta complexed with… | x-ray diffraction | C, D | — | — |
| 1ZAF | Crystal structure of estrogen receptor beta complexed with… | x-ray diffraction | C, D | — | — |
| 2A3I | Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator… | x-ray diffraction | B | — | — |
| 2A3I | Structural and biochemical mechanisms for the specificity of hormone binding and coactivator… | x-ray diffraction | B | — | — |
| 2C52 | Structural diversity in CBP p160 complexes | solution nmr | B | — | — |
| 2C52 | Structural diversity in cbp P160 complexes | solution nmr | B | — | — |
| 2FVJ | A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG)… | x-ray diffraction | B | — | — |
| 2FVJ | A novel anti-adipogenic partial agonist of peroxisome proliferator- activated receptor-gamma… | x-ray diffraction | B | — | — |
| 2GTK | Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists | x-ray diffraction | B | — | — |
| 2GTK | Structure-based design of indole propionic acids as novel pparag co- agonists | x-ray diffraction | B | — | — |
| 2HBH | Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain… | x-ray diffraction | B | — | — |
| 2HBH | Crystal structure of vitamin D nuclear receptor ligand binding domain bound to a locked side-chain… | x-ray diffraction | B | — | — |
| 2HC4 | Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol | x-ray diffraction | B | — | — |
| 2HC4 | Crystal structure of the lbd of vdr of danio rerio in complex with calcitriol | x-ray diffraction | B | — | — |
| 2HCD | Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with… | x-ray diffraction | B | — | — |
| 2HCD | Crystal structure of the ligand binding domain of the vitamin D nuclear receptor in complex with… | x-ray diffraction | B | — | — |
| 2NV7 | Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555 | x-ray diffraction | C, D | — | — |
| 2NV7 | Crystal structure of estrogen receptor beta complexed with way-555 | x-ray diffraction | C, D | — | — |
| 2P54 | a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 | x-ray diffraction | B | — | — |
| 2P54 | A crystal structure of ppar alpha bound with SRC1 peptide and GW735 | x-ray diffraction | B | — | — |
| 3BEJ | Structure of human FXR in complex with MFA-1 and co-activator peptide | x-ray diffraction | E, F | — | — |
| 3BEJ | Structure of human fxr in complex with mfa-1 and co-activator peptide | x-ray diffraction | E, F | — | — |
| 3BQD | Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol | x-ray diffraction | B | — | — |
| 3BQD | Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol | x-ray diffraction | B | — | — |
| 3CTB | Tethered PXR-LBD/SRC-1p apoprotein | x-ray diffraction | A, B | — | — |
| 3CTB | Tethered pxr-LBD/SRC-1P apoprotein | x-ray diffraction | A, B | — | — |
| 3CWD | Molecular recognition of nitro-fatty acids by PPAR gamma | x-ray diffraction | C, D | — | — |
| 3CWD | Molecular recognition of nitro-fatty acids by ppar gamma | x-ray diffraction | C, D | — | — |
| 3DCT | FXR with SRC1 and GW4064 | x-ray diffraction | B | — | — |
| 3DCT | Fxr with SRC1 and GW4064 | x-ray diffraction | B | — | — |
| 3DCU | FXR with SRC1 and GSK8062 | x-ray diffraction | B | — | — |
| 3DCU | Fxr with SRC1 and GSK8062 | x-ray diffraction | B | — | — |
| 3DR1 | Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D… | x-ray diffraction | B | — | — |
| 3DR1 | Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D… | x-ray diffraction | B | — | — |
| 3ET1 | Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid | x-ray diffraction | P, Q | — | — |
| 3ET1 | Structure of pparalpha with 3-[5-methoxy-1-(4-methoxy- benzenesulfonyl)-1H-indol-3-yl]-propionic… | x-ray diffraction | P, Q | — | — |
| 3ET3 | Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid | x-ray diffraction | P | — | — |
| 3ET3 | Structure of ppargamma with 3-[5-methoxy-1-(4-methoxy- benzenesulfonyl)-1H-indol-3-yl]-propionic… | x-ray diffraction | P | — | — |
| 3FEI | Design and biological evaluation of novel, balanced dual PPARa/g agonists | x-ray diffraction | Z | — | — |
| 3FEI | Design and biological evaluation of novel, balanced dual PPARA/G agonists | x-ray diffraction | Z | — | — |
| 3FEJ | Design and biological evaluation of novel, balanced dual PPARa/g agonists | x-ray diffraction | B | — | — |
| 3FEJ | Design and biological evaluation of novel, balanced dual PPARA/G agonists | x-ray diffraction | B | — | — |
| 3FUR | Crystal Structure of PPARg in complex with INT131 | x-ray diffraction | H | — | — |
| 3FUR | Crystal structure of pparg in complex with INT131 | x-ray diffraction | H | — | — |
| 3FXV | Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist | x-ray diffraction | B | — | — |
| 3FXV | Identification of an N-oxide pyridine GW4064 analogue as a potent fxr agonist | x-ray diffraction | B | — | — |
| 3G8I | Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II… | x-ray diffraction | Z | — | — |
| 3G8I | Aleglitazar, a new, potent, and balanced ppar ALPHA/GAMMA agonist for the treatment of type II… | x-ray diffraction | Z | — | — |
| 3G9E | Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes | x-ray diffraction | B | — | — |
| 3G9E | Aleglitaar. a new. potent, and balanced dual PPARA/G agonist for the treatment of type II diabetes | x-ray diffraction | B | — | — |
| 3H0A | Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid… | x-ray diffraction | B, E | — | — |
| 3H0A | Crystal structure of peroxisome proliferator-activated receptor gamma (pparg) and retinoic acid… | x-ray diffraction | B, E | — | — |
| 3HC5 | FXR with SRC1 and GSK826 | x-ray diffraction | B | — | — |
| 3HC5 | Fxr with SRC1 and GSK826 | x-ray diffraction | B | — | — |
| 3HC6 | FXR with SRC1 and GSK088 | x-ray diffraction | B | — | — |
| 3HC6 | Fxr with SRC1 and GSK088 | x-ray diffraction | B | — | — |
216 records more on the page itself.
Ligands
- GRH · (2~{R})-~{N}-[4-(3-chloranylphenoxy)-3-sulfamoyl-phenyl]-2-phenyl-propanamide · in 2 records
- L7D · 1,1,1,3,3,3-hexafluoro-2-(4-{1-[(4-fluorophenyl) sulfonyl]cyclopentyl}phenyl)propan-2-ol · in 2 records
- Z8I · (3R,5S)-3-fluoro-5-[(3ar,9br)-9B-[(4-fluorophenyl) sulfonyl]-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-1, 2,3A,4,5,9B-hexahydro-3H-benzo[e]indole-3-carbonyl]-1-(2-hydroxy-2-methylpropyl)pyrrolidin-2-one · in 2 records
- G3L · Nomilin · in 1 record
- N6H · [2-[(3-chlorophenyl)methylamino]-7-methoxy-1,3-benzoxazol-5-yl]-(2,2-dimethylmorpholin-4-yl)methanone · in 1 record
- O5A · Trans-4-{(3R)-3-[(4-fluorophenyl)sulfonyl]-3-[4-(1,1,1, 2,3,3,3-heptafluoropropan-2-yl)phenyl]pyrrolidine-1-carbonyl}cyclohexane-1-carboxylic acid · in 1 record
- O5B · Trans-4-[(3ar,9br)-9B-[(4-fluorophenyl)sulfonyl]-7-(1, 1,1,2,3,3,3-heptafluoropropan-2-yl)-1,2,3A,4,5,9B-hexahydro-3H-benzo[e]indole-3-carbonyl]cyclohexane-1-carboxylic acid · in 1 record
- PO4 · Phosphate ion · in 1 record
- QCG · (2S)-tert-butoxy[7-(8-fluoro-5-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-6-yl]acetic acid · in 1 record
- TKJ · 4-{(3R)-3-[4-(benzyloxy)phenyl]-3-[(4-fluorophenyl) sulfonyl]pyrrolidine-1-carbonyl}-1lambda~6~-thiane-1, 1-dione · in 1 record
- WT1 · (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-5-methyl-1-(2,4,5-trimethoxyphenyl)-1H-1,2,3-triazole-4-carboxamide · in 1 record
- WU6 · methyl 3-{[(1P)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carbonyl]amino}-4-{[(3S)-hexan-3-yl]oxy}benzoate · in 1 record
- XGH · 2-[(2S)-4-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-(2-hydroxy-2-methylpropyl) acetamide · in 1 record
- Z7D · 1-(benzyloxy)-4-{1-[(4-fluorophenyl) sulfonyl]cyclopentyl}benzene · in 1 record
- Z7G · {3,5-dichloro-4-[4-methoxy-3-(propan-2-yl) phenoxy]phenyl}methanol · in 1 record
- Z7H · N-{3,5-dichloro-4-[4-methoxy-3-(propan-2-yl) phenoxy]phenyl}-2-(pyridin-3-yl)acetamide · in 1 record
- Z7I · N-(3,5-dichloro-4-{[6-methoxy-5-(propan-2-yl)pyridin-3-yl]oxy}phenyl)-2-[1-(methylsulfonyl)piperidin-4-yl]acetamide · in 1 record
Experiment against prediction
- 8SVT chain A against the predicted model O75469: TM-score 0.95, RMSD 1.04 Å
- 7CHG chain A against the predicted model O75469: TM-score 0.95, RMSD 0.81 Å
- 3CTB chain A against the predicted model O75469: TM-score 0.95, RMSD 0.74 Å
- 3CTB chain A against the predicted model O75469: TM-score 0.95, RMSD 0.74 Å
- 6BNS chain A against the predicted model O75469: TM-score 0.95, RMSD 0.73 Å
- 3HVL chain A against the predicted model O75469: TM-score 0.94, RMSD 0.76 Å
- 3HVL chain A against the predicted model O75469: TM-score 0.94, RMSD 0.76 Å
- 6NX1 chain A against the predicted model O75469: TM-score 0.94, RMSD 0.88 Å
- 6NX1 chain A against the predicted model O75469: TM-score 0.94, RMSD 0.88 Å
- 8SVR chain A against the predicted model O75469: TM-score 0.94, RMSD 0.76 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.